Merck To Settle Suits Alleging Jaw Damage From Osteoporosis Drug

Merck To Settle Suits Alleging Jaw Damage From Osteoporosis Drug

WHITEHOUSE STATION, N.J. - Merck & Co. Inc. has agreed to pay $27.7 million to resolve product liability suits alleging that its osteoporosis drug Fosamax caused osteonecrosis of the jaw (ONJ), or bone death, according to a press release the company issued Dec. 9 (In Re: Fosamax Products Liability Litigation, No. 1:06md1789, S.D. N.Y.).

Find full version on lexis Advance®
Access this news story on lexis.com®